Furthermore, patient survival analysis using data obtained from the TCGA-ACC cohort indicates that low SYTL5 mRNA expression is associated with a significantly reduced survival of ACC patients (Figure 6C), suggesting a possible tumour suppressor function for SYTL5 in ACC cancer progression. The gene discussed is SYTL5; the disease is adrenal cortex carcinoma.